BST1 and acute myeloid leukemia: To combine the antibody-mediated approach with genetic manipulation of CD157 expression in AML cells, we extended our studies using U937, THP1 (both AML FAB M5 subtype) and OCI-AML3 (AML FAB M4 subtype) human AML cell lines which express variable levels of CD157 mRNA and protein (Supplementary Fig. S3A,B,D) almost entirely consisting of the canonical CD157/BST-1 protein from the 9-exon transcript encoded by BST133 (Supplementary Fig. S3C).